<DOC>
	<DOCNO>NCT00217763</DOCNO>
	<brief_summary>The purpose Phase 3 study evaluate efficacy safety 3APS add-on therapy standard medication Alzheimer 's disease compare placebo ( inactive substance pill ) patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>European Study 3APS Mild Moderate Alzheimer 's Disease Patients</brief_title>
	<detailed_description>- Duration treatment : 18 month - 3 treatment arm : Placebo 2 different dos active drug .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Tramiprosate</mesh_term>
	<criteria>RECRUITMENT OF PARTICIPANTS IS PERFORMED ONLY BY STUDY SITES . INCLUSION CRITERIA : Participants must meet follow inclusion criterion eligible . Male Female ( age 50 year old ) : Female must nonchildbearing potential ( i.e . surgically sterilize least 2 year postmenopausal ) . Diagnosis probable Alzheimer 's disease base National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA criterion ) . Severity dementia mild moderate degree assess Mini Mental State Examination ( MMSE ) perform screen visit . Patient must live community reliable caregiver . Participant living assist living facility may include study medication intake supervise participant reliable caregiver . Potential participant must treat acetylcholinesterase inhibitor ( donepezil , galantamine rivastigmine ) must stable dose least 4 month prior screen visit entire study period . Participants must take memantine least 4 month prior commencement screening . The use memantine prohibit course study . Fluency ( oral write ) language standardized test administer . Signed informed consent potential participant legal representative caregiver . EXCLUSION CRITERIA : Patients eligible participate study meet follow criterion : Potential participant cause dementia . Life expectancy le 2 year . Potential participant clinically significant and/or uncontrolled condition significant medical disease . Previous use antiamyloid vaccine treatment Alzheimer 's disease . Use investigational drug within 30 day prior screen visit entire study . Previous exposure 3APS . Inability swallow pill .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's disease</keyword>
</DOC>